Home / Drug discovery / Drug delivery / Polymers
Advanced polymers in drug delivery
We design, synthesize, and analyze advanced polymers for drug delivery and conjugation applications. Our chemistry teams develop polymer-based drug delivery systems with defined molecular weight range, solubility, and release characteristics, supported by high-precision purification and analytical expertise.
As a CRO drug delivery partner, we help clients advance complex formulations and meet regulatory expectations with confidence.
Capabilities include:
- Polymer nanoparticles (PMPs) – Design, synthesis and scale-up (including GMP) of polymers for RNA, mRNA and DNA delivery for precise targeting, enhanced stability and improved delivery performance
- Polymer-drug conjugation – Custom linkers designed to enhance solubility, extend stability, and enable targeted release – supporting safer, more effective drug delivery and controlled therapeutic outcomes.
- Material science polymers – Specialty and surface-functionalized polymers developed for medical and dental devices, engineered through RAFT-CT techniques enable desired characteristics (Mw, Mn, Mp, Mz and PDI) to fit your exact performance, stability, and application-specific characteristics.
- Analytical and purification expertise – Tangential flow filtration chromatography (TFF), gel permeation chromatography (GPC), size exclusion chromatography (SEC) and advanced preparative techniques ensure polymers meet exact specifications to deliver consistent and reproducible quality.
Related services
Polymer chemistry expertise
15+ years of expertise
Well established in advancing polymer chemistry for drug delivery and material science applications.
Flexible delivery
Rapid and flexible synthesis turnaround and courier delivery for your urgent polymer drug delivery needs.
Integrated polymer capabilities
Advanced polymerization, analytics and scale-up under one roof with seamless IND-enabling support.
Polymer and lipid expertise in drug delivery
Our polymer programs connect directly with our lipid chemistry capabilities to create delivery materials tailored for nucleic acid and small-molecule therapeutics.
By combining expertise in custom and catalog lipids – including helper lipids, PEGs, PEG replacements, and GalNAc conjugates – we optimize formulation performance, improve stability, and accelerate the transition from discovery to clinical development.
What do our partners say?
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
Your discovery and development partner
We support programs from target exploration through IND, combining assay biology, ADME-tox, medicinal chemistry, and CMC development.
With laboratories in Europe and North America, projects remain closely supported across all phases of drug discovery and development
Resources we think you'll love
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Whitepaper
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Whitepaper
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Connect with our polymer drug delivery experts
See how we can support the discovery and development of your next breakthrough.